Table 1.
Baseline characteristics of the two groups
| Pitavastatin group (n = 65) | Atorvastatin group (n = 67) | P value | |
|---|---|---|---|
| Age (yr.) | 65.8±10.5 | 65.3±9.3 | 0.7724 |
| Male-n (%) | 40 (61.5) | 43 (64.2) | 0.8936 |
| BMI (kg/m2) | 24.2±3.4 | 24.5±3.7 | 0.6287 |
| Waist circumference (cm) | 87.1±8.8 | 86.4±9.5 | 0.6615 |
| History | |||
| Hypertension-n (%) | 43 (66.2) | 40 (59.7) | 0.5572 |
| Family history of CAD-n (%) | 14 (21.5) | 15 (22.4) | 0.9264 |
| Smoking-n (%) | 32 (50.8) | 34 (50.7) | 1.0000 |
| Alcohol drinker-n (%) | 33 (50.8) | 29 (43.3) | 0.4920 |
| Diabetes-n (%) | 29 (44.6) | 28 (41.8) | 0.8794 |
| Types of ACS | 0.8756 | ||
| Unstable angina-n (%) | 35 (53.8) | 38 (56.7) | |
| NSTEMI-n (%) | 30 (46.2) | 29 (43.3) | |
| GRACE score | 167±37 | 170±40 | 0.6556 |
| CRUSADE score | 34.7±10.2 | 33.8±8.1 | 0.4548 |
| SBP (mmHg) | 127±5.8 | 129±7.6 | 0.0923 |
| Heart rate (bpm) | 74±3.5 | 73±3.2 | 0.0841 |
| Hemoglobin (g/L) | 140.6±12.2 | 141.8±13.4 | 0.5918 |
| Hs-CRP (mg/L) | 10.3±5.5 | 10.5±6.1 | 0.8436 |
| eGFR- (mL/min/1.73 m2) | 74.5±16.1 | 72.6±15.2 | 0.4868 |
| LVEF (%) | 54.2±7.1 | 54.9±8.3 | 0.6040 |
| Drug administration | |||
| Aspirin-n (%) | 65 (100) | 66 (98.5) | 1.000 |
| Clopidogrel-n (%) | 61 (93.8) | 60 (89.6) | 0.5313 |
| β-blocker-n (%) | 59 (90.8) | 59 (88.1) | 0.8399 |
| Calcium blocker-n (%) | 30 (46.2) | 28 (41.8) | 0.7418 |
| Diuretics-n (%) | 11 (16.9) | 12 (17.9) | 0.9363 |
| ACEI/ARB-n (%) | 54 (83.1) | 58 (86.6) | 0.7517 |
| Insulin-n (%) | 3 (4.6) | 4 (6.0) | 1.000 |
| Nitrate-n (%) | 23 (35.4) | 26 (38.8) | 0.8207 |
| Sulfonylurea-n (%) | 8 (12.3) | 7 (10.4) | 0.9503 |
| α-glucosidase inhibitor-n (%) | 9 (13.8) | 8 (11.9) | 0.9466 |
Note: BMI: body mass index; CAD: coronary artery disease; ACS: acute coronary syndrome; NSTEMI: non-ST segment elevated myocardial infarction; SBP: systolic blood pressure; hs-CRP: high-sensitivity C-reactive protein; eGFR: estimated glomerular filtration rate; LVEF: left ventricle ejection fraction; ACEI/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker.